Diagnosis and Treatment of Neuroendocrine Lung Tumors;Diagnóstico y tratamiento de los tumores pulmonares neuroendocrinos

Archivos de Bronconeumologia

Volumn 50, Issue 9, 2014, Pages 392-396

  de Cos Escuín, Julio Sánchez ^a  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

Author keywords

Classification; Diagnosis; Pulmonary neuroendocrine tumors; Treatment

Indexed keywords

SOMATOSTATIN; SOMATOSTATIN DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; CARCINOID SYNDROME; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METASTASIS POTENTIAL; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PULMONARY NEUROENDOCRINE TUMOR; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; CARCINOID TUMOR; CARCINOMA, LARGE CELL; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; BENIGN NEOPLASM; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER THERAPY; CARCINOID; DIAGNOSTIC TEST; SMALL CELL LUNG CANCER; TREATMENT RESPONSE; TUMOR DIAGNOSIS;

CARCINOID TUMOR; CARCINOMA, LARGE CELL; HUMANS; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS;

EID: 84906937296     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbres.2014.02.004     Document Type: Short Survey

References (37)

1. Kulke M.H., Mayer R.J. Carcinoids tumors. N Eng J Med 1999, 340:858-868.
2. Kosmidis P.A. The spectrum of carcinoids tumors. Lung Cancer. Principles and Practice. 2010, 971-979. Lippincott, Williams and Wilkins, Filadelfia. H.I. Pass, D.P. Carbone, D.H. Johnson, D.H. Minna, A.T. Turrisi (Eds.).
3. Rekhtman N. Neuroendocrine tumors of the lung. An update. Arch Pathol Lab Med 2010, 134:1628-1638.
4. Gridelli C., Rossi A., Airoma G., Bianco R., Costanzo R., Daniele B., et al. Treatment of pulmonary neuroendocrine tumors: State of the art and future developments. Cancer Treat Rev 2013, 39:466-472.
5. Lim E., Goldstraw P., Nicholson A.G., Travis W.D., Jett J.R., Ferolla P., et al. Proceedings of the IASLC International workshop on advances in pulmonary neuroendocrine tumors 2007. J Thorac Oncol 2008, 3:1194-1201.
6. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. Pathology & Genetics. Tumors of the lung, pleura, thymus and heart 2004, IARC Press - World Health Organization Classification of Tumors, Lyon, France.
7. Ferolla P., Daddi N., Urbani M., Semeraro A., Ribacchi R., Giovenali P., et al. Tumorlets, multicentric carcinoids, lymph-nodal metastases, and long-term behavior in bronchial carcinoids. J Thorac Oncol 2009, 4:383-387.
8. Travis W.D. Advances in neuroendocrine lung tumors. Ann Oncol 2010 2010, (Suppl 7):vii65-vii71.
9. Rossi G., Cavazza A., Marchioni A., Longo L., Migaldi M., Sartori G., et al. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRa, PDGFRb and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol 2005, 23:8874-8885.
10. Masters G.A. Clinical presentation of small cell lung cancer. Lung Cancer. Principles and Practice 2010, 341-351. Lippincott, Williams and Wilkins, Philadelphia. H.I. Pass, D.P. Carbone, D.H. Johnson, D.H. Minna, A.T. Turrisi (Eds.).
11. De Leyn P., Didier L., Van Schill P.E., Rami-Porta, Passlick B., Zielinski M., et al. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg 2007, 32:1-8.
12. Sánchez de Cos J., Hernández J., Jiménez M., Padrones S., Rossell A., Rami-Porta R. Normativa SEPAR sobre estadificación del cáncer de pulmón. Arch Bronchoneumol 2011, 47:454-465.
13. Lim E., Baldwin D., Beckles M., Duffy J., Entwisle J., Faivre-Finn C., et al. Guidelines on the radical management of patients with lung cancer. Thorax 2011, 65(Suppl III):1-27.
14. 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 2009, 50:1927-1932.
15. Shepherd F.A., Crowley J., van Houtte P., Postmus P.E., Carney D., Chansky K., et al. The International Association for the Study of Lung Cancer staging project: Proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007, 2:1067-1077.
16. Travis W.D., Girouk D.J., Chansky K., Crowley J., Asamura H., Brambilla E., et al. The IASLC Lung Cancer Staging project: Proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for lung cancer. J Thorac Oncol 2008, 3:1213-1223.
17. Ignatius Ou S.-H., Zell J.A. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th edition. J Thorac Oncol 2009, 4:300-310.
18. Vallières E., Shepherd F.A., Crowley J., van Houtte P., Postmus P., Carney D., et al. Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009, 4:1049-1059. The IASLC lung cancer staging project.
19. Filosso P.L., Oliaro A., Ruffini E., Bora G., Lyberis P., Asioli F., et al. Outcome and prognostic factors in bronchial carcinoids. A single center experience. J Thorac Oncol 2013, 8:1282-1288.
20. García-Yuste M., Matilla J.M., Álvarez-Gago T., Duque J.L., Heras F., Cerezal, et al. Prognostic factors in neuroendocrine lung tumors: A Spanish multicenter study. Ann Thorac Surg 2000, 70:258-263.
21. García-Yuste M., Matilla J.M., Cueto A., Rodríguez Paniagua J.M., Ramos G., Cañizares M.A., et al. Typical and atypical carcinoid tumours: Analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung. Eur J Cardiothorac Surg 2007, 31:192-197.
22. Beasley M.B., Thunnisen F.B., Brambilla E., Hasleton P., Steele R., Hammar S.P., et al. Pulmonary atypical carcinoids: Predictors of survival in 106 cases. Hum Pathol 2000, 31:1255-1265.
23. Sculier J-P., Chansky K., Crowley J.J., van Meerbeeck J., Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition. J Thorac Oncol 2008, 3:457-466. International Staging Committee and Participating Institutions.
24. Thomas J.R., Tazelaar H.D., Jett J.R. Typical and atypical pulmonary carcinoids: Outcome in patients presenting with regional lymph node involvement. Chest 2001, 119:1143-1150.
25. National Cancer Comprehensive Center - Clinical practice guidelines in Oncology - Small cell lung cancer. Version 2.2013 [consultado 12 Ago 2013]. Disponible en: http://www,nccn.org.
26. Wirtz L.J., Carter M.R., Jänne P.A., Johnson B.E. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 2004, 44:213-220.
27. Pavel E., Hainsworth J., Baudin E., Peeters M., Hörsch D., Winkler R.E., et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 2011, 378:2005-2012.
28. Kölby L., Persson G., Franzén S., Ahrén B. Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003, 90:687-693.
29. Yao J.C., Phan A., Hoff P.M., Chen H.X., Chusilp C., Yeung S.-C., et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alfa-2 beta. J Clin Oncol 2008, 26:1316-1323.
30. Hirsch F.R., Spreafico A., Novello S., Wood M.D., Simms L., Papotti M. The prognostic and predicitive role of histology in advanced non-small cell lung cancer. J Thorac Oncol 2008, 3:1468-1481.
31. Iyoda A., Hiroshima K., Moriya Y., Iwadate Y., Takiguchi Y., Uno T., et al. Postoperative recurrence and the role of adjuvanrt chemotherapy in patients with pulmonary large cell carcinoma. J Thorac Cardiovasc Surg 2009, 138:446-453.
32. Yamakazi S., Sekine I., Matsuno Y., Takei H., Yamamoto N., Kunitoh H., et al. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer 2005, 49:217-223.
33. Shimada Y., Niho S., Ishii G., Hishida T., Yoshida J., Nishimura M., et al. Clinical features of unresectable high-grade lung neuroendocrine carcinoma diagnosed using biopsy specimens. Lung Cancer 2012, 75:368-373.
34. Sun J.M., Ahn M.J., Ahn J.S., Um S.W., Kim H., Kim H.-K., et al. Chemotherapy for pulmonary large-cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer?. Lung Cancer 2012, 77:365-370.
35. Niho S., Kenmotsu H., Sekine I., Ishii G., Ishikawa Y., Noguchi M., et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroencocrine carcinoma of the lung. A multicenter phase II study. J Thorac Oncol 2013, 10:980-984.
36. De Pas T.M., Giovannini M., Manzotti M., Trifiro G., Toffalorio F., Catania Ch, et al. Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J Clin Oncol 2011, 29:819-822.
37. Jett J.R., Schild S.E., Kesler K.A., Kalemkerian G.P. Treatment of small cell lung cancer diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143(5 Suppl):e400S-e1900S.